TIEMONIUM

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H24NO2S
Molecular Weight	318.454
Optical Activity	( + / - )
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

C[N+]3(CCC(O)(C1=CC=CS1)C2=CC=CC=C2)CCOCC3

InChI

InChIKey=HJDYAOBDPZQHOD-UHFFFAOYSA-N

InChI=1S/C18H24NO2S/c1-19(11-13-21-14-12-19)10-9-18(20,17-8-5-15-22-17)16-6-3-2-4-7-16/h2-8,15,20H,9-14H2,1H3/q+1

HIDE SMILES / InChI

Molecular Formula	C18H23NO2S
Molecular Weight	317.446
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF | https://www.ncbi.nlm.nih.gov/pubmed/187134

Tiemonium (often used in a form of iodide or methylsulphate salt) is a muscarinic acetylcholine receptor antagonist, which is available in Asia (mainly Bangladesh) for the alleviation of muscle spasms of the intestine, biliary system, uterus and urinary bladder in gastrointestinal, biliary, urinary and gynecological diseases.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor 162 Target ID: CHEMBL2094109 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8822036 \| https://www.ncbi.nlm.nih.gov/pubmed/187134	Antagonist 2849

Conditions

Condition	Modality	Highest Phase	Product
Gastroenteritis 10 Sources: http://www.squarepharma.com.bd/downloads/Norvis.pdf	Palliative	Approved 8583	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Diarrhea 36 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8583	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Dysentery 7 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8583	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Biliary colic 4 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8583	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Enterocolitis 4 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8583	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Cholecystitis 12 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8583	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Colonopathies 4 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8583	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Mild cystitis 4 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8583	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Spasmodic dysmenorrhoea 4 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8583	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.

Doses

Dose	Population	Adverse events
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://www.aci-bd.com/Brand/Tynium.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.aci-bd.com/Brand/Tynium.pdf	Sources: https://www.aci-bd.com/Brand/Tynium.pdf

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443
6,7-Difluoro-1,4-dihydro-1-methyl-4-oxo-3-quinolinecarboxylic acid, a newly designed fluorescence enhancement-type derivatizing reagent for amino compounds.	2010-03	20108029
Direct asymmetric catalytic thienylaluminum addition to ketones: a concise approach to the synthesis of (S)-tiemonium iodide.	2009-08-06	19588914
Orofacial dyskinesia associated with tiemonium.	2007-12	18034667

Patents

Sample Use Guides

In Vivo Use Guide

Recommended oral dose of tiemonium (in form of methylsulphate salt) tablet is 2-6 tablets (100-300 mg) daily in divided dosage as required. Tiemonium can be also given as an injection (5 or 10 mg) three times daily, through Intravenous route or Intramuscular route. Suppository: recommended dose is 1 suppository (each suppository contains 20 mg methylsulphate salt) two or three times daily, through rectal route.

Route of Administration: Other

In Vitro Use Guide

Human colon cancer cell lines, LOVO, were incubated in 2 ml of fresh complete medium containing 10(-2) M tiemonium methylsulfate for five days. Under the tested concentration tiemonium methylsulfate lead to a decrease of cell proliferation.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:18:01 GMT 2025` Edited by `admin` on `Mon Mar 31 18:18:01 GMT 2025`
Record UNII	5Y5LZ9A0KV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TIEMONIUM

Common Name

English

TIEMONIUM CATION

Preferred Name

English

4-(3-HYDROXY-3-PHENYL-3-(2-THIENYL)PROPYL)-4-METHYL-MORPHOLINIUM

Systematic Name

English

Tiemonium [WHO-DD]

Common Name

English

TIEMONIUM ION

Common Name

English

Classification Tree Code System Code

WHO-ATC

A03AB17